Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

(2018) Susan O’Brien et al.   BLOOD

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

(2018) Paul M. Barr et al.   HAEMATOLOGICA

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy

(2018) Jan A. Burger et al.   Nature Reviews Clinical Oncology

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

(2018) Paul M. Barr et al.   HAEMATOLOGICA

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

(2018) Anthony R. Mato et al.   HAEMATOLOGICA

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies

(2018) Tadeusz Robak et al.   AMERICAN JOURNAL OF HEMATOLOGY

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

(2018) Anthony R. Mato et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation

(2018) Valeria Buccheri et al.   ANNALS OF HEMATOLOGY

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

(2018) Carol Moreno et al.   LANCET ONCOLOGY

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

(2018) G. Fraser et al.   LEUKEMIA

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

(2017) Steven Coutre et al.   HAEMATOLOGICA

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

(2017) J R Brown et al.   LEUKEMIA

Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

(2017) Steven Coutre et al.   HAEMATOLOGICA

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

(2017) Jennifer R. Brown et al.   HAEMATOLOGICA

Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base

(2016) Alina M. Mateo et al.   ANNALS OF SURGICAL ONCOLOGY

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

(2016) Barbara Eichhorst et al.   LANCET ONCOLOGY

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

New treatment approaches in CLL: Challenges and opportunities in the elderly

(2016) Barbara Eichhorst et al.   Journal of Geriatric Oncology

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

(2015) M. L. Wang et al.   BLOOD

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

(2009) B. F. Eichhorst et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD